Comparing the effect of liquid phase concentrated growth factors with 2% lidocaine in the management of patients with myofascial pain syndrome

Comparing the pain control effect of liquid phase concentrated growth factors with Lidocaine 2%, masseter and temporalis muscle trigger points and pain free mouth opening in patients with myofascial pain syndrome

Status

Recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20220610055126N1

Enrollment

Registered

2022-06-14

Start date

2022-06-13

Completion date

Unknown

Last updated

2022-06-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

patients with myofascial pain syndrome.

Interventions

Intervention 1: Intervention group: In this group of patients, we use LPCGF injection to control the pain of trigger points in one session. First we find the muscle trigger points in the master or tem

Then we disinfect the patient's skin with medical alcohol. Dot the trigger points with disinfected white cosmetic pencil and then take 10 ml of blood from the patient's vein (this step is done by a sp

Silfradent S.r.l, Sofia, Italy) (Figure -2) (this step is performed by a specialist assistant under the supervision of a consultant in the operating room of the gingival surgery department. The exact

Eligibility

Sex/Gender

All

Age

15 Years to 80 Years

Inclusion criteria

Inclusion criteria: Age between 15 and 80 years [=15 and =80] Presence of at least one trigger point in the masseter or temporalis muscle, previously detected Patient’s agreement for participation in this study. Presence of myofascial pain within masseter muscles according to the RDC/TMD (Ia and Ib)

Exclusion criteria

Exclusion criteria: Patients being treated or addicted to painkillers and / or drugs that affect muscle function. Such as: muscle relaxants, anti-inflammatory, benzodiazepines Patients with mental disorders Patients with neuropathic pain and neurological disorders (trigeminal neuralgia) Patients with headache Edentulous patients Patients after radiotherapy Pregnancy or lactation Pain of dental origin Drug and/or alcohol addiction Patients with needle phobia Patients with bleeding disorders Metabolic (diabetes) and vascular diseases

Design outcomes

Primary

Measure	Time frame
Pain intensity of masseter muscle trigger points, pain intensity of temporalis muscle trigger points, general pain intensity, painless opening of mouth. Timepoint: At the beginning of the study (before the start of the intervention) and 7, 14 and 28 days. Method of measurement: Visual Analogue Scale for pain intensity and measurement with a graduated millimeter with an accuracy of one millimeter for maximum mouth opening.	—

Measure

Time frame

Pain intensity of masseter muscle trigger points, pain intensity of temporalis muscle trigger points, general pain intensity, painless opening of mouth. Timepoint: At the beginning of the study (before the start of the intervention) and 7, 14 and 28 days. Method of measurement: Visual Analogue Scale for pain intensity and measurement with a graduated millimeter with an accuracy of one millimeter for maximum mouth opening.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactMarzieh Alimohammadi

Shahid Beheshti University of Medical Sciences

m.alimohamadi95@yahoo.com+98 21 2217 5351

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026